National and Kapodistrian University of Athens
Μοριακή μελέτη της παθογένειας των χρόνιων μυελοϋπερπλαστικών συνδρόμων
Abstract
dc:descriptionMyeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells characterized by proliferation of one or more myeloid cell lines (granulocytic, megakaryocytic, and mast cells). According to the World Health Organization (WHO) classification, these include classic MPN Philadelphia chromosome (Ph)-negative diseases which include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The discovery of recurrent molecular abnormalities such as JAK2V617F and MPL W515L/K has reinforced the original idea of Dameshek in 1951 that these diseases share a common pathogenetic mechanism and presumably belong to a single disorder. Clonality studies have established that PV, ET, and MF are diseases that originate from a common hematopoietic stem cell that is hypersensitive to the action of growth factors. The result is an autonomous proliferation of hematopoietic colonies, which leads to overproduction of red blood cells, platelets, and leukocytes. Among these disorders, ET has the most favorable outcome. Patients with ET have a lifespan that nearly rivals that of healthy population matched by age and sex. However, the life expectancy of patients with PV and ET is strongly affected by disease-related hemostatic complications, including thrombosis and, to a lesser extent, hemorrhages. Clinical manifestations of thrombosis vary from mild microcirculatory disturbances to more serious complications such as arterial and venous thrombosis. Pregnancy is a hypercoagulable condition and in combination with MPN creates a profound thrombotic milieu, leading to an increased risk for placental thrombosis, fetal growth retardation or loss, and maternal thrombotic events, particularly deep vein thrombosis and PE.Aim of this study was the delineation of the underlying molecular mechanisms that are involved in the pathogenesis of Chronic Myeloproliferative Neoplasms, as well as the investigation of the genetic substrate of patients with MPN that have been fully characterized but share different phenotypic and laboratory characteristics. Results summarized further below:i.We studied 895 patients with MPN and CML and we identified 42 new cases that were positive for the BCR-ABL fusion, while 138 patients had been formerly diagnosed and now are monitored at molecular level in our laboratory. Additionally, two new cases of patients were diagnosed with B-ALL Ph1 (+).Additionally, we investigated 221 patients with suspicion of HES for the presence of fusion genes involving receptor tyrosine kinases (PDGFRA, PDGFRB, FGFR1), and we identified the FIP1L1-PDGFRA fusion gene in six patients, while only one out of 221 patients carried the ETV6-PDGFRB rearrangement.ii.In the whole of 895 patients, we detected the JAK2 V617F mutation in 306 patients. The mutation was detected in almost all patients with PV and in 50% of patients with ET and MF, remarkably. It is obvious that the identification of JAK2 V617F mutation constitutes one of the most significant steps in clarification of the molecular pathogenesis of MPNs.iii.We also investigated 31 patients with PV that were negative for the JAK2 V617F mutation, in order to identify exon 12 mutations of the JAK2 gene. N542-E543del mutation was identified in three patients and K539L in only one patient. F537-K539delinsL and H538QK539L mutations were identified in none of this cohort of patients.iv.We also investigated 90 patients with essential thrombocythemia, 19 patients with secondary thrombocytosis, and 19 patients with myelofibrosis, all JAK2 V617F-negative, for the presence of exon 10 mutations of the MPL gene. Six patients with ET and three patients with MF harbor the MPLW515L/K mutations, while none of the patients with secondary thrombocyotisis carried mutations of MPL gene.v.Finally, we investigated disease entities that are associated with thrombotic complications for the identification of mutations in JAK2 and MPL genes. We studied 389 women with history of recurrent miscarriage, though neither JAK2 nor MPL mutations were detected in any case. We also enrolled 147 patients with no evidence of an MPN who suffered an acute myocardial infraction under the age of 35 years. JAK2 and MPL mutations were detected in none of the patients investigated. Eventually, we studied 52 consecutive patients with no evidence of an underlying MPN who had been diagnosed with retinal vein occlusion for the presence of mutations in JAK2 and MPL genes. Overall, MPN associated mutations were detected in 5/52 cases. JAK2V617F was detected in 2/52 cases, while MPL exon 10 mutations were detected in 3/52. Our findings indicate that a latent MPN could underlie RVO even in the absence of conventional diagnostic criteria. Our results represent the first report that MPL mutations could underlie RVO cases and suggest that routine screening of RVO cases for MPN mutations may be useful.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zoi, Christine
- Ζώη, Χριστίνα
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35671